Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 1 shares, an increase of ∞ from the June 30th total of 0 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 1,653 shares, the days-to-cover ratio is currently 0.0 days.
Starpharma Stock Performance
Shares of SPHRY opened at $4.89 on Friday. Starpharma has a 12-month low of $0.67 and a 12-month high of $5.70. The business’s fifty day moving average is $4.77 and its 200 day moving average is $4.00.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
See Also
- Five stocks we like better than Starpharma
- Generac’s AI Power Story Is Becoming Bigger Than the Weather
- Everyone’s Focused on China—But That’s Not ASML’s Biggest Risk
- Chipotle Mexican Grill Stock Rallies as Q2 Results Top Fears, Guidance Rises
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
